Michael J Bloch
Overview
Explore the profile of Michael J Bloch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloch M, Azizi M, Kirtane A, Mahfoud F, Sharp A, McGuire M, et al.
EuroIntervention
. 2025 Jan;
21(1):93-95.
PMID: 39773825
No abstract available.
2.
Bloch M, Kirtane A, Azizi M, Mahfoud F, Basile J, Daemen J, et al.
Hypertens Res
. 2024 Sep;
47(12):3467-3472.
PMID: 39333663
Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This...
3.
Mufarrih S, Qureshi N, Khan M, Kazimuddin M, Secemsky E, Bloch M, et al.
J Am Heart Assoc
. 2024 Aug;
13(16):e034910.
PMID: 39140334
Background: Despite optimal medical therapy, a significant proportion of patients' blood pressure remains uncontrolled. Catheter-based renal denervation (RDN) has been proposed as a potential intervention for uncontrolled hypertension. We conducted...
4.
Azizi M, Sharp A, Fisher N, Weber M, Lobo M, Daemen J, et al.
Circulation
. 2023 Oct;
149(10):747-759.
PMID: 37883784
Background: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System...
5.
Kirtane A, Sharp A, Mahfoud F, Fisher N, Schmieder R, Daemen J, et al.
JAMA Cardiol
. 2023 Feb;
8(5):464-473.
PMID: 36853627
Importance: Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of the uRDN effect across the HTN...
6.
Azizi M, Saxena M, Wang Y, Jenkins J, Devireddy C, Rader F, et al.
JAMA
. 2023 Feb;
329(8):651-661.
PMID: 36853250
Importance: Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment. Objective: To...
7.
Azizi M, Mahfoud F, Weber M, Sharp A, Schmieder R, Lurz P, et al.
JAMA Cardiol
. 2022 Nov;
7(12):1244-1252.
PMID: 36350593
Importance: Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham...
8.
Kandzari D, Townsend R, Bakris G, Basile J, Bloch M, Cohen D, et al.
Catheter Cardiovasc Interv
. 2021 Aug;
98(3):416-426.
PMID: 34343406
No abstract available.
9.
Mahfoud F, Bloch M, Azizi M, Wang Y, Schmieder R, Lobo M, et al.
EuroIntervention
. 2021 Jul;
17(12):e1024-e1032.
PMID: 34236037
Background: The multicentre, randomised, sham-controlled RADIANCE-HTN SOLO trial reported the blood pressure (BP)-lowering efficacy and safety of ultrasound renal denervation (RDN) in the absence (2 months) and presence (6 and...
10.
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study
Saxena M, Schmieder R, Kirtane A, Mahfoud F, Daemen J, Basile J, et al.
J Hum Hypertens
. 2021 May;
36(7):629-639.
PMID: 34031548
The blood pressure (BP) lowering response to renal denervation (RDN) remains variable with about one-third of patients not responding to ultrasound or radiofrequency RDN. Identification of predictors of the BP...